Drug Target Review

What Drug Target Review does

Drug Target Review is a B2B digital media brand covering drug discovery news, research, and industry insights for pharmaceutical, biotechnology, and academic research professionals. The platform publishes daily news articles, expert-authored feature articles, opinion pieces, webinars, and in-depth reports spanning therapeutic areas (with a focus on oncology and emerging modalities) and enabling technologies including AI, organoids, spatial biology, and gene therapy. Its core product is a web-based publishing platform with a registered membership program, weekly newsletter, and an active webinar and virtual events program. The business operates on a dual revenue model: sponsored content, webinars, and reports from life sciences vendors (tools, instruments, CROs, and pharma/biotech companies such as Sartorius, Leica Microsystems, Bio-Techne, Merck, Agilent, Danaher, WuXi Biologics, Miltenyi, and others) and a freemium membership model that gates exclusive content and builds a first-party audience for sponsor lead generation.

Drug Target Review is owned and operated by Russell Publishing Limited, a privately held, family-run UK B2B media company headquartered in Brasted, Kent, that also publishes European Pharmaceutical Review, New Food, Global Railway Review, and International Airport Review, and operates the related Drug Discovery Events property. The team is small (12 employees), and the publication runs a community-led go-to-market model in which free editorial content drives registration, which in turn fuels the audience sold to enterprise sponsors. Pricing is freemium at the reader level; paid premium tiers are not publicly disclosed. The platform maintains a global editorial footprint, with coverage of research from institutions in the US, UK, Europe, Australia, Japan, and Singapore.

From a strategic positioning perspective, Drug Target Review is a defensible niche media property rather than a technology company: its competitive logic is audience aggregation in a specialized vertical, monetized through sponsor relationships rather than subscription or software ARR. Growth signals include expansion into new editorial verticals (AI, Oncology), new content formats (deep-dive reports, AACR conference coverage), and a widening roster of enterprise sponsors, but there is no disclosed revenue, fundraising, or headcount growth data, and the core technology is a standard content management and digital publishing platform without proprietary AI or data products.

Name

Drug Target Review

Legal name

Russell Publishing Limited

Website

https://drugtargetreview.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Drug Target Review is a B2B digital media publication serving pharmaceutical and biotechnology drug discovery professionals with news, expert articles, webinars, and reports, monetized through enterprise sponsorships and a freemium registered membership model.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Drug Discovery Media

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Pharmaceutical media
• Drug discovery news
• Biotech publishing
• Life sciences webinars
• B2B scientific content

Headquarters

HQ city

Brasted, Kent

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Sponsored Content and Webinars: Life sciences companies (pharma, biotech vendors, CROs) sponsor webinars, whitepapers, and sponsored articles on the platform, paying for access to the drug discovery professional audience.
2. Membership/Subscription: Free membership registration provides access to exclusive content, reports, webinars, and a weekly newsletter. The freemium model converts readers into registered members who represent leads for sponsors.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Drug Target Review is a B2B digital media publication that delivers news, expert-authored articles, sponsored webinars, and in-depth reports on drug discovery research, technologies, and industry developments for pharmaceutical, biotech, and life sciences research professionals. The platform operates on a freemium membership model, with free registration providing access to articles, newsletters, and webinars, while sponsored content from life sciences vendors (pharma, biotech, CROs, tool providers) serves as the primary revenue driver.

Product overview

Drug Target Review is a publication-based platform offering a unified content ecosystem for drug discovery professionals. The core offering is the Drug Target Review Website, which publishes articles, news, and analysis on drug discovery topics. This is supplemented by a Webinars program featuring live and on-demand expert discussions often sponsored by industry partners, and a Reports section providing in-depth analysis on specialized topics such as spatial biology and organoids. A membership program offers exclusive access to content, newsletters, and additional resources. The platform is operated by Russell Publishing and focuses on serving the pharmaceutical and biotechnology research community.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Target Review Website A drug discovery news publication providing articles, news, analysis, and industry insights for professionals in pharmaceutical and biotechnology research. The site publishes daily editorial content organized across topics including technology, diseases, drugs and therapies, research and development, tools and techniques, and business.
• Drug Target Review Webinars Live and on-demand webinar programming featuring expert discussions on drug discovery topics, often sponsored by industry partners such as Sartorius, Agilent, Merck, Danaher Life Sciences, and WuXi Biologics. Topics covered include therapeutic antibodies, NAMs in drug discovery, membrane proteins, neuronal metabolism, and genomic medicine manufacturing.
• Drug Target Review Reports In-depth reports on specialized drug discovery topics including spatial biology, organoids, and emerging therapeutic approaches. Reports are often sponsored by industry vendors such as Miltenyi Biotec for the spatial biology report.
• Drug Target Review Membership Program Free membership registration providing access to exclusive content, reports, webinars, and a weekly newsletter. The freemium model converts readers into registered members who represent leads for sponsors.

Quantifiable outcome

• Multiple articles published weekly covering latest research in AI drug discovery, oncology, organoids, gene therapy, and other therapeutic areas

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

17 partnerships are on record, tiered core and standard.

• SartoriuscoreGTM or Marketing PartnerSartorius sponsors multiple webinars and content pieces on the platform, including topics on advanced flow cytometry (iQue platform), live-cell analysis (Incucyte), and antibody binding assays. The partnership provides educational content to the drug discovery audience.
• Leica MicrosystemscoreGTM or Marketing PartnerLeica Microsystems sponsors microscopy-related content including application notes on multiplex imaging, cancer stem cell niches, microscope cameras, and spatial biology. The partnership provides technical guides to the audience.
• Bio-TechnecoreGTM or Marketing PartnerBio-Techne sponsors content on GMP protein qualification, organoids, and serum-free/animal-free research methodologies.
• BPS BiosciencestandardGTM or Marketing PartnerBPS Bioscience sponsors assay-related content including fluorescence polarization assays, Fc receptor binding, and ADC-related educational materials.
• BellBrook LabsstandardGTM or Marketing PartnerBellBrook Labs sponsors content on helicase assays using the Transcreener platform and methyltransferase assays (PRMT5, MLL4, METTL3/14).
• Takara Bio USAstandardGTM or Marketing PartnerTakara Bio USA sponsors content on single-cell genome profiling, mRNA synthesis workflows, and CRISPR-related topics.
• AgilentcoreGTM or Marketing PartnerAgilent sponsors webinars on topics including neuronal metabolism in early drug discovery and XF real-time ATP rate assays.
• MerckcoreGTM or Marketing PartnerMerck sponsors AI in drug discovery content including webinars and application notes on protein sample preparation.
• Danaher Life SciencescoreGTM or Marketing PartnerDanaher Life Sciences sponsors webinars on personalized CRISPR therapy and scalable precision genomic medicine manufacturing.
• WuXi BiologicscoreGTM or Marketing PartnerWuXi Biologics sponsors content on TCR discovery and cell therapy development workflows.
• Eurofins DiscoverystandardGTM or Marketing PartnerEurofins Discovery sponsors obesity drug discovery webinar content.
• AbzenastandardGTM or Marketing PartnerAbzena sponsors content on antibody-oligonucleotide conjugate (AOC) chemistry, manufacturing, and regulatory strategies.
• HUB OrganoidsstandardGTM or Marketing PartnerHUB Organoids sponsors content on organoid technology and NAMs in early drug discovery.
• Analytik Jena GmbH + Co. KGstandardGTM or Marketing PartnerAnalytik Jena sponsors content on membrane protein purification and analysis.
• Miltenyi BiotecstandardGTM or Marketing PartnerMiltenyi Biotec sponsors the spatial biology report and related content.
• YokogawastandardGTM or Marketing PartnerYokogawa sponsors content on high-content imaging automation at scale.
• Russell Publishing LimitedcoreStrategic or Co-development PartnerDrug Target Review is owned and operated by Russell Publishing Limited, a family-run B2B media company. Russell Publishing also operates related events properties including Drug Discovery Events and European Pharmaceutical Review.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Citeline / In Vivo (Informa): Large pharma intelligence portfolio including In Vivo, Scrip, Pink Sheet, and trial/drug databases. Broader incumbent in the same drug development information category with significantly more resources and a wider enterprise data footprint than DTR.

Direct peers

• Drug Discovery & Development: Trade title covering drug discovery technologies, tools, and pipelines with a similar target audience of researchers and tools vendors. Direct competitor in the drug discovery trade media category.
• BioCentury: Long-established biopharma intelligence publisher covering R&D, business, and policy across the drug development value chain. Closely comparable as a deep drug-discovery/development trade media and intelligence brand.
• Labiotech.eu: European-headquartered biotech news platform covering drug development and the European life sciences ecosystem. Directly comparable as a regional B2B media brand competing for European drug discovery audience and sponsors.
• BioSpace: Biopharma news and careers platform serving industry professionals across R&D and commercialization. Comparable to DTR in serving drug discovery professionals with a sponsorship- and employer-supported revenue mix.
• BioWorld (Clarivate): Subscription-based biopharma news service from Clarivate covering drug development pipelines. Comparable to DTR as a professional drug discovery news platform, though with a heavier paid-subscription orientation.
• Endpoints News: Independent biopharma news outlet with a subscriber-supported model covering R&D, clinical development, and the business of drug discovery. Comparable as a niche drug development media brand competing for similar audience attention.
• Fierce Biotech / Fierce Pharma: Flagship B2B pharma/biotech trade news brands covering drug development and commercialization. Directly comparable to DTR as a sponsorship-supported media platform serving the same drug discovery and pharma professional audience.
• Genetic Engineering & Biotechnology News (GEN): Long-running trade publication covering drug discovery, genomics, and biotechnology tools. Competes head-to-head with DTR for life sciences vendor sponsorship budgets and drug discovery professional readership.
• Pharma Times: Established pharma industry news outlet covering R&D, clinical development, and commercialization. Comparable as a general pharma trade media brand competing for overlapping sponsor audiences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/drugtargetreview
• LinkedInlinkedin.com/company/drug-target-review

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Target Review